Annual CFO
-$18.09 M
-$733.90 K-4.23%
31 December 2023
Summary:
Inhibikase Therapeutics annual cash flow from operations is currently -$18.09 million, with the most recent change of -$733.90 thousand (-4.23%) on 31 December 2023. During the last 3 years, it has fallen by -$16.96 million (-1501.29%). IKT annual CFO is now -2629.37% below its all-time high of $715.00 thousand, reached on 31 December 2018.IKT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$4.88 M
+$173.30 K+3.43%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly cash flow from operations is currently -$4.88 million, with the most recent change of +$173.30 thousand (+3.43%) on 30 September 2024. Over the past year, it has dropped by -$776.00 thousand (-18.90%). IKT quarterly CFO is now -6565.03% below its all-time high of $75.50 thousand, reached on 30 September 2020.IKT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$17.24 M
-$776.00 K-4.71%
30 September 2024
Summary:
Inhibikase Therapeutics TTM cash flow from operations is currently -$17.24 million, with the most recent change of -$776.00 thousand (-4.71%) on 30 September 2024. Over the past year, it has increased by +$954.10 thousand (+5.24%). IKT TTM CFO is now -9676.02% below its all-time high of -$176.40 thousand, reached on 30 September 2020.IKT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -4.2% | -18.9% | +5.2% |
| 3 y3 years | -1501.3% | -141.6% | -54.7% |
| 5 y5 years | -2629.4% | -10000.0% | -4904.3% |
IKT Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1501.3% | at low | -141.6% | +18.3% | -54.7% | +12.0% |
| 5 y | 5 years | -2629.4% | at low | -6565.0% | +18.3% | -9676.0% | +12.0% |
| alltime | all time | -2629.4% | at low | -6565.0% | +18.3% | -9676.0% | +12.0% |
Inhibikase Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.88 M(-3.4%) | -$17.24 M(+4.7%) |
| June 2024 | - | -$5.05 M(+30.7%) | -$16.47 M(+3.1%) |
| Mar 2024 | - | -$3.87 M(+12.3%) | -$15.98 M(-11.6%) |
| Dec 2023 | -$18.09 M(+4.2%) | -$3.44 M(-16.1%) | -$18.09 M(-0.6%) |
| Sept 2023 | - | -$4.11 M(-10.1%) | -$18.20 M(-7.1%) |
| June 2023 | - | -$4.57 M(-23.6%) | -$19.60 M(+1.1%) |
| Mar 2023 | - | -$5.97 M(+67.9%) | -$19.39 M(+11.7%) |
| Dec 2022 | -$17.35 M(+21.4%) | -$3.56 M(-35.4%) | -$17.35 M(-3.0%) |
| Sept 2022 | - | -$5.50 M(+26.4%) | -$17.89 M(+24.2%) |
| June 2022 | - | -$4.36 M(+10.7%) | -$14.41 M(+0.8%) |
| Mar 2022 | - | -$3.93 M(-3.9%) | -$14.30 M(0.0%) |
| Dec 2021 | -$14.30 M | -$4.10 M(+102.7%) | -$14.30 M(+28.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | -$2.02 M(-52.4%) | -$11.15 M(+23.2%) |
| June 2021 | - | -$4.25 M(+7.9%) | -$9.05 M(+88.3%) |
| Mar 2021 | - | -$3.93 M(+315.7%) | -$4.81 M(+325.8%) |
| Dec 2020 | -$1.13 M(+233.8%) | -$946.50 K(-1353.6%) | -$1.13 M(+540.2%) |
| Sept 2020 | - | $75.50 K(-2703.4%) | -$176.40 K(-31.8%) |
| June 2020 | - | -$2900.00(-98.9%) | -$258.70 K(-15.2%) |
| Mar 2020 | - | -$255.40 K(-4090.6%) | -$304.90 K(-9.8%) |
| Dec 2019 | -$338.30 K(-147.3%) | $6400.00(-194.1%) | -$338.20 K(-1.9%) |
| Sept 2019 | - | -$6800.00(-86.2%) | -$344.60 K(+2.0%) |
| June 2019 | - | -$49.10 K(-83.0%) | -$337.80 K(+17.0%) |
| Mar 2019 | - | -$288.70 K | -$288.70 K |
| Dec 2018 | $715.00 K | - | - |
FAQ
- What is Inhibikase Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual CFO year-on-year change?
- What is Inhibikase Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly CFO year-on-year change?
- What is Inhibikase Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics TTM CFO year-on-year change?
What is Inhibikase Therapeutics annual cash flow from operations?
The current annual CFO of IKT is -$18.09 M
What is the all time high annual CFO for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual cash flow from operations is $715.00 K
What is Inhibikase Therapeutics annual CFO year-on-year change?
Over the past year, IKT annual cash flow from operations has changed by -$733.90 K (-4.23%)
What is Inhibikase Therapeutics quarterly cash flow from operations?
The current quarterly CFO of IKT is -$4.88 M
What is the all time high quarterly CFO for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly cash flow from operations is $75.50 K
What is Inhibikase Therapeutics quarterly CFO year-on-year change?
Over the past year, IKT quarterly cash flow from operations has changed by -$776.00 K (-18.90%)
What is Inhibikase Therapeutics TTM cash flow from operations?
The current TTM CFO of IKT is -$17.24 M
What is the all time high TTM CFO for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM cash flow from operations is -$176.40 K
What is Inhibikase Therapeutics TTM CFO year-on-year change?
Over the past year, IKT TTM cash flow from operations has changed by +$954.10 K (+5.24%)